Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease
American heart journal, 2012•Elsevier
BACKGROUND: Left atrial enlargement, a sensitive integrator of left ventricular diastolic
function, is associated with increased cardiovascular morbidity and mortality. Vitamin D is
linked to lower cardiovascular morbidity, possibly modifying cardiac structure and function;
however, firm evidence is lacking. We assessed the effect of an activated vitamin D analog
on left atrial volume index (LAVi) in a post hoc analysis of the PRIMO trial (clinicaltrials. gov:
NCT00497146). METHODS AND RESULTS: One hundred ninety-six patients with chronic …
function, is associated with increased cardiovascular morbidity and mortality. Vitamin D is
linked to lower cardiovascular morbidity, possibly modifying cardiac structure and function;
however, firm evidence is lacking. We assessed the effect of an activated vitamin D analog
on left atrial volume index (LAVi) in a post hoc analysis of the PRIMO trial (clinicaltrials. gov:
NCT00497146). METHODS AND RESULTS: One hundred ninety-six patients with chronic …
BACKGROUND
Left atrial enlargement, a sensitive integrator of left ventricular diastolic function, is associated with increased cardiovascular morbidity and mortality. Vitamin D is linked to lower cardiovascular morbidity, possibly modifying cardiac structure and function; however, firm evidence is lacking. We assessed the effect of an activated vitamin D analog on left atrial volume index (LAVi) in a post hoc analysis of the PRIMO trial (clinicaltrials.gov: NCT00497146).
METHODS AND RESULTS
One hundred ninety-six patients with chronic kidney disease (estimated glomerular filtration rate 15-60 mL/min per 1.73m2), mild to moderate left ventricular hypertrophy, and preserved ejection fraction were randomly assigned to 2 μg of oral paricalcitol or matching placebo for 48 weeks. Two-dimensional echocardiography was obtained at baseline and at 24 and 48 weeks after initiation of therapy. Over the study period, there was a significant decrease in LAVi (−2.79 mL/m2, 95% CI −4.00 to −1.59 mL/m2) in the paricalcitol group compared with the placebo group (−0.70 mL/m2 [95% CI −1.93 to 0.53 mL/m2], P = .002). Paricalcitol also attenuated the rise in levels of brain natriuretic peptide (10.8% in paricalcitol vs 21.3% in placebo, P = .02). For the entire population, the change in brain natriuretic peptide correlated with change in LAVi (r = 0.17, P = .03).
CONCLUSIONS
Forty-eight weeks of therapy with an active vitamin D analog reduces LAVi and attenuates the rise of BNP. In a population where only few therapies alter cardiovascular related morbidity and mortality, these post hoc results warrant further confirmation.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果